Fulgent Genetics (NASDAQ:FLGT) Insider Hanlin Gao Sells 945 Shares

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 945 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $17.60, for a total value of $16,632.00. Following the transaction, the insider directly owned 992,062 shares of the company’s stock, valued at approximately $17,460,291.20. The trade was a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Fulgent Genetics Price Performance

Shares of FLGT traded up $0.34 during midday trading on Thursday, reaching $18.24. The stock had a trading volume of 478,192 shares, compared to its average volume of 502,915. The company has a market capitalization of $518.03 million, a P/E ratio of -7.63 and a beta of 0.88. The firm’s 50 day moving average price is $16.04 and its 200-day moving average price is $21.94. Fulgent Genetics, Inc. has a 52 week low of $13.46 and a 52 week high of $31.04.

Fulgent Genetics (NASDAQ:FLGT) last announced its earnings results on Friday, February 27th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative return on equity of 3.24% and a negative net margin of 23.04%.The business had revenue of $83.34 million during the quarter, compared to analysts’ expectations of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450–1.450 EPS. On average, equities analysts forecast that Fulgent Genetics, Inc. will post -2.81 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on FLGT. Wall Street Zen lowered shares of Fulgent Genetics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Zacks Research cut Fulgent Genetics from a “strong-buy” rating to a “hold” rating in a report on Monday, February 9th. Finally, Piper Sandler reiterated a “neutral” rating and set a $15.00 price objective (down from $30.00) on shares of Fulgent Genetics in a research report on Tuesday, May 5th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Fulgent Genetics currently has an average rating of “Hold” and a consensus price target of $27.00.

Institutional Investors Weigh In On Fulgent Genetics

A number of large investors have recently made changes to their positions in FLGT. Farther Finance Advisors LLC lifted its position in shares of Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock valued at $35,000 after acquiring an additional 548 shares in the last quarter. Kestra Advisory Services LLC acquired a new position in Fulgent Genetics in the 4th quarter worth approximately $35,000. Caitong International Asset Management Co. Ltd boosted its stake in Fulgent Genetics by 214.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock worth $48,000 after purchasing an additional 1,251 shares during the period. Raymond James Financial Inc. acquired a new position in Fulgent Genetics in the 2nd quarter worth approximately $49,000. Finally, Flagship Harbor Advisors LLC acquired a new position in Fulgent Genetics in the 4th quarter worth approximately $56,000. Institutional investors and hedge funds own 48.06% of the company’s stock.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.